Daratumumab, an IgG kappa monoclonal antibody against CD38, is commonly used in patients with MM (4–8), with overall response rates (ORR) ranging from 40-90% of relapsed/refractory MM patients. The gene discussed is CD38; the disease is Miyoshi myopathy.